open access

Vol 52, No 2 (2021)
Short communication
Submitted: 2021-04-09
Accepted: 2021-04-09
Get Citation

Myelodysplasia-associated Sweet’s syndrome: clinical and laboratory presentation and response to thalidomide

Bartlomiej Wawrzycki1, Dariusz Jawniak2, Aldona Pietrzak1, Justyna Szumilo3, Dorota Krasowska1
DOI: 10.5603/AHP.2021.0020
Acta Haematol Pol 2021;52(2):132-136.
  1. Chair and Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland
  2. Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
  3. Chair and Department of Clinical Pathomorphology, Medical University of Lublin, Lublin, Poland

open access

Vol 52, No 2 (2021)
Submitted: 2021-04-09
Accepted: 2021-04-09


Not available


Not available
Get Citation
About this article

Myelodysplasia-associated Sweet’s syndrome: clinical and laboratory presentation and response to thalidomide


Acta Haematologica Polonica


Vol 52, No 2 (2021)

Article type

Short communication



Page views


Article views/downloads




Bibliographic record

Acta Haematol Pol 2021;52(2):132-136.


Bartlomiej Wawrzycki
Dariusz Jawniak
Aldona Pietrzak
Justyna Szumilo
Dorota Krasowska

References (28)
  1. Vignon-Pennamen MD. Sweet's syndrome. In: Wallach D, Vignon-Pennamen MD, Valerio Marzano A. ed. Neutrophilic dermatoses. Springer International Publishing, Cham 2018: 13–35.
  2. Nelson CA, Stephen S, Ashchyan HJ, et al. Neutrophilic dermatoses: pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol. 2018; 79(6): 987–1006.
  3. Lepelletier C, Bouaziz JD, Rybojad M, et al. Neutrophilic dermatoses associated with myeloid malignancies. Am J Clin Dermatol. 2019; 20(3): 325–333.
  4. Hoffbrand AV, Vyas P, Campo E, Haferlach T, Gomez K. Color atlas of clinical hematology. Wiley Blackwell, Hoboken 2018: 256–270.
  5. Van Loon K, Gill RM, McMahon P, et al. 20q- clonality in a case of oral sweet syndrome and myelodysplasia. Am J Clin Pathol. 2012; 137(2): 310–315.
  6. Nelson CA, Noe MH, McMahon CM, et al. Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018; 78(2): 303–309.e4.
  7. Kulasekararaj AG, Kordasti S, Basu T, et al. Chronic relapsing remitting Sweet syndrome — a harbinger of myelodysplastic syndrome. Br J Haematol. 2015; 170(5): 649–656.
  8. Vignon-Pennamen MD, Juillard C, Rybojad M, et al. Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. Arch Dermatol. 2006; 142(9): 1170–1176.
  9. Kakaletsis N, Kaiafa G, Savopoulos C, et al. Initially lymphocytic Sweet's syndrome in male patients with myelodysplasia: a distinguished clinicopathological entity? Case report and systematic review of the literature. Acta Haematol. 2014; 132(2): 220–225.
  10. Mekinian A, Grignano E, Braun T, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016; 55(2): 291–300.
  11. Navarini AA, Satoh TK, French LE. Neutrophilic dermatoses and autoinflammatory diseases with skin involvement — innate immune disorders. Semin Immunopathol. 2016; 38(1): 45–56.
  12. Fenini G, Contassot E, French LE. Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseases. Front Pharmacol. 2017; 8: 278.
  13. Wallach D, Vignon-Pennamen MD. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses. Br J Dermatol. 2018; 178(3): 595–602.
  14. Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018; 132(15): 1553–1560.
  15. Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019; 133(10): 1039–1048.
  16. Heath MS, Ortega-Loayza AG. Insights into the pathogenesis of Sweet's syndrome. Front Immunol. 2019; 10: 414.
  17. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1): 22–32.
  18. Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol. 2008; 27(3): 111–135.
  19. Keller M, Sollberger G, Beer HD. Thalidomide inhibits activation of caspase-1. J Immunol. 2009; 183(9): 5593–5599.
  20. Lee C, Do HT, Her J, et al. Inflammasome as a promising therapeutic target for cancer. Life Sci. 2019; 231: 116593.
  21. Lee DJ, Li H, Ochoa MT, et al. Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Infect Dis. 2010; 201(4): 558–569.
  22. Yasui K, Kobayashi N, Yamazaki T, et al. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des. 2005; 11(3): 395–401.
  23. Lauridsen HM, Pellowe AS, Ramanathan A, et al. Tumor necrosis factor-α and IL-17A activation induces pericyte-mediated basement membrane remodeling in human neutrophilic dermatoses. Am J Pathol. 2017; 187(8): 1893–1906.
  24. Browning CE, Dixon JE, Malone JC, et al. Thalidomide in the treatment of recalcitrant Sweet's syndrome associated with myelodysplasia. J Am Acad Dermatol. 2005; 53(2 Suppl 1): S135–S138.
  25. Fozza C, La Nasa G, Caocci G. The Yin and Yang of myelodysplastic syndromes and autoimmunity: the paradox of autoimmune disorders responding to therapies specific for MDS. Crit Rev Oncol Hematol. 2019; 142: 51–57.
  26. Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15(11): e493–e503.
  27. Bastuji-Garin S, Ochonisky S, Bouche P, et al. Thalidomide Neuropathy Study Group. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002; 119(5): 1020–1026.
  28. Tamburini J, Elie C, Park S, et al. Groupe Francophone des Myélodysplasies, GFM. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leuk Res. 2009; 33(4): 547–550.


Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: